Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

PVP Biologics Scores Support from Takeda for Celiac Disease Treatment



Celiac disease affects one percent of the world’s population, according to estimates made by the Celiac Disease Foundation.

Share this!

January 9, 2017 | by Sarah Hand, M.Sc.

Takeda Pharmaceuticals and PvP Biologics have entered into a global agreement to co-develop an enzyme – called KumaMax – designed to help treat patients with celiac disease. The enzyme, which was developed by the biotech startup, helps break down gluten in the stomach to prevent the allergen from triggering an immune reaction and causing damage to the small intestine.

“Takeda’s GI experience and capabilities are a great fit with our goal of developing a novel oral enzyme therapy to make a meaningful impact on the lives of people with celiac disease,” said Adam Simpson, president and CEO of PvP Biologics. “In addition, the significant non-dilutive financing provided by Takeda will accelerate therapeutic development of KumaMax.”

PvP Biologics has agreed to conduct all required research and development through Phase I clinical trials. Takeda will provide $35 million in financing, with the option to acquire the biotech after reviewing the data.

“This agreement with PvP Biologics reinforces Takeda’s commitment to developing therapeutics targeting celiac disease. KumaMax could address a significant unmet need for celiac patients who try, but are unable to completely avoid gluten exposure in their diets, and thus continue to experience debilitating symptoms,” said Asit Parikh, head of the gastroenterology therapeutic area for Takeda. “We are pleased to be partnering with PvP Biologics, a company whose management team has a proven track record of successfully bringing assets that target chronic inflammatory gastrointestinal diseases through development.”

KumaMax is a recombinant enzyme which is currently in preclinical development. Enzymatically active at the low pH found in the stomach, KumaMax specifically targets the parts of the gluten protein that stimulate an autoimmune response. There is no treatment for celiac patients, aside from completely avoiding the allergen by adhering to a limiting gluten-free diet.

“Celiac disease is a disorder in which the ingestion of even a trace amount of gluten can damage the small intestine,” said Dr. Tadataka "Tachi" Yamada, chairman of PvP Biologics. “In pre-clinical experiments, KumaMax has shown the ability to degrade gluten with sufficient efficiency and effectiveness to indicate its exciting potential as an oral therapy for a disease that impairs the lives of millions.”

KumaMax could provide a fail-safe for celiac patients who inadvertently ingest gluten, by degrading the allergen before it can enter the small intestine. This could reduce the painful symptoms and intestinal damage associated with accidental gluten consumption.

Celiac disease affects one percent of the world’s population, according to estimates made by the Celiac Disease Foundation. Celiac disease can progress with exposure to gluten, causing gastrointestinal discomfort, malnutrition and weakness.

Keywords: Celiac Disease, Gluten, Biotech


Share this with your colleagues!

New Self-Injectable Form of Lupus Drug Approved by the FDA

July 25, 2017 - Patients with systemic lupus erythematosus (SLE) will now have the option to self-inject their medication thanks to the FDA approval of GSK’s reformulated lupus drug, Benlysta (belimumab).

Featured In: Biotech News

Canadian Chicken Farmers to Further Reduce Use of Antibiotics

July 24, 2017 - The Chicken Farmers of Canada, a national group dedicated to supporting poultry farmers and helping them meet consumer demand for chicken, has announced their strategy for eliminating the use of certain antimicrobials in meat production.

Featured In: Food News

Neonatal MRI Medical Device Approved by the FDA

July 24, 2017 - Medical device maker Aspect Imaging has received US Food and Drug Administration (FDA) approval for its Embrace Neonatal MRI System.

Featured In: Medical Device News


Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know


Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned

EDC and eSource: Combined for Better Data and Faster Insights

Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide

How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology

Copyright © 2016-2017 Honeycomb Worldwide Inc.